182
Participants
Start Date
August 31, 2012
Primary Completion Date
April 30, 2014
Study Completion Date
April 30, 2014
Oral testosterone undecanoate
Total daily dose of T = 200 mg T (as 316 mg TU) to 600 mg T (as 948 mg TU), taken as 100 mg to 300 mg T BID
Transdermal testosterone gel (AndroGel)
Total daily dose of T = 2.5 to 10 g of gel (25 mg to 100 mg T) QD
University Urology Associates, New York
Michael A. Werner, Purchase
Bruce R. Gilbert, MD, PhD, Great Neck
Maimonides Medical Center, Brooklyn
Urologic Consultants of Southeast Pennsylvania, Bala-Cynwyd
Johns Hopkins University, Baltimore
South Florida Medical Research, Aventura
Alabama Clinical Therapeutics, Calera
Alabama Clinical Therapeutics, Inc., Birmingham
Alabama Internal Medicine, PC, Birmingham
Medical Affiliated Research Center, Inc, Huntsville
University of Louisville, Louisville
University of Muenster, Center for Reproduction and Andrology, Münster
University of Bonn, Clinic for Dermatology and Allergy, Bonn
Research Across America, Carrollton
Research Across America, Dallas
Quality of Life Medical and Research Centers, LLC, Tucson
Tower Urology, Los Angeles
David Geffen School of Medicine, UCLA, Los Angeles
Harbor-UCLA Medical Center, LA Biomedical Research Institute, Torrance
Providence Clinical Research, Burbank
South Orange County Endocrinology, Laguna Hills
Sunstone Medical Research, Medford
University of Washington, Seattle
Connecticut Clinical Research Center/ConnecTrials, Middlebury
University of CT School of Medicine, New Haven
Boston University School of Medicine, Boston
University of Halle, Center for Reproduction and Andrology, Halle
Praxis Dr. Szymula, Leipzig
Praxis Dr. Schulze, Markkleeberg
Lead Sponsor
Clarus Therapeutics, Inc.
INDUSTRY